• Vyne Therapeutics held a special shareholder meeting on July 16, 2026 focused on a merger with Yarrow.
• Shareholders authorized the share issuance to Yarrow holders under the merger agreement, clearing the vote required to proceed with the transaction.
• A reverse stock split was adopted, with the final ratio to be set later by the board within a 1-for-10 to 1-for-70 range.
• An increase in authorized common shares to 300 million was adopted.
• The Yarrow Bioscience 2026 Stock Incentive Plan was adopted.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-084760), on July 20, 2026, and is solely responsible for the information contained therein.